Raymond James Financial »

Enliven Therapeutics shares owned by Raymond James Financial

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Raymond James Financial from 13F filings

Historical chart of Raymond James Financial investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Raymond James Financial consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Raymond James Financial

Quarter filed Position value Share count Share price at filing
2026-03-31 $416k 11k 39.20

More positions owned by Raymond James Financial

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Apple (AAPL)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Broadcom (AVGO)
Amazon (AMZN)
JPMorgan Chase & Co. (JPM)
Ishares Tr Core Msci Eafe (IEFA)
Alphabet Cap Stk Cl A (GOOGL)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Wal-Mart Stores (WMT)
Ishares Tr Core S&p500 Etf (IVV)
Johnson & Johnson (JNJ)
Ishares Tr Core S&p Mcp Etf (IJH)

View all positions for Raymond James Financial

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Polar Capital Holdings
BlackRock
Commodore Capital
Vestal Point Capital
Bellevue Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
State Street Corporation
Geode Capital Management
Logos Global Management
Caption Management

View all funds holding Enliven Therapeutics